These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 22741415)
1. Face-off will new drugs pay off in time to counter patent losses for Forest Laboratories? Vukhac K; Rivkind I Fortune; 2012 Jun; 165(8):80. PubMed ID: 22741415 [No Abstract] [Full Text] [Related]
3. How companies stall generics and keep themselves healthy. Stolberg SG; Gerth J N Y Times Web; 2000 Jul; ():A1, A14, A15. PubMed ID: 11785519 [No Abstract] [Full Text] [Related]
4. Pills, patents, and power: state creation of gray markets as a limit on patent rights. Ghosh S Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138 [No Abstract] [Full Text] [Related]
5. The people vs patents. New Sci; 2002 Jul; 175(2351):3. PubMed ID: 12625337 [No Abstract] [Full Text] [Related]
6. The Cipro patent and bioterrorism. Kaye KS; Kaye D Am J Bioeth; 2002; 2(3):41-2. PubMed ID: 12230854 [No Abstract] [Full Text] [Related]
7. Maximizing exclusivity for drug products. French H Nat Rev Drug Discov; 2005 Sep; 4(9):709. PubMed ID: 16178117 [No Abstract] [Full Text] [Related]
8. Biotech patents-business as usual? Lawrence S Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861 [No Abstract] [Full Text] [Related]
9. Redesigner drugs. Dove A Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643 [TBL] [Abstract][Full Text] [Related]
10. Patent reform in the US: what's at stake for pharmaceutical innovation? Yancey A; Stewart CN Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544 [TBL] [Abstract][Full Text] [Related]
11. Drug patent plan gets mixed reviews. Butler D Nature; 2009 Feb; 457(7233):1064. PubMed ID: 19256077 [No Abstract] [Full Text] [Related]
12. Pharmaceutical patent settlements: the antitrust risks. Balto DA Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464 [No Abstract] [Full Text] [Related]
13. Issues in bringing new drugs to the market. Tracey WR Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329172 [No Abstract] [Full Text] [Related]
14. Intellectual property. Balancing innovation and access: patent challenges tip the scales. Higgins MJ; Graham SJ Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944 [No Abstract] [Full Text] [Related]
16. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering. Paine CS Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807 [No Abstract] [Full Text] [Related]
17. Reference pricing of pharmaceuticals. Brekke KR; Königbauer I; Straume OR J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769 [TBL] [Abstract][Full Text] [Related]
18. Should the patent system for new medicines be abolished? DiMasi JA; Grabowski HG Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100 [No Abstract] [Full Text] [Related]
19. More drugs, less protection. Nature; 2002 Sep; 419(6904):233. PubMed ID: 12239521 [No Abstract] [Full Text] [Related]